Amgen Inc.
AMGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. With a market capitalization of $197.69B, it sits in large-cap territory. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEP.
Market Cap
$197.69B
Beta
0.40
P/E (TTM)
25.83
P/E (Fwd)
15.62
EPS (TTM)
$14.18
EPS (Fwd)
$23.45
ROE
101.3%
ROA
8.3%
Cash
$12.04B
Total Debt
$57.32B
Free CF
$7.44B
52W Change
24.3%
Annual Financials
Cash vs Debt
On the balance sheet, AMGN has $12.04B in cash with $57.32B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $7.44B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 101.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $26.32B (2022) to $36.75B (2025), reflecting a 40% increase over the period.
With a beta below 0.7, Amgen Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing AMGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.